Lit Matters 3: Safety of High Dose Nitroglycerin Therapy in SCAPE

SCAPE is a hypertensive acute heart failure emergency driven by sudden afterload excess, and early vasodilation is central to treatment. High-dose nitroglycerin appears reasonably safe in severe sympathetic crashing acute pulmonary edema, but the bedside dosing strategy and the role of alternatives like nicardipine remain unsettled.

High-Dose Nitroglycerin in SCAPE

• Afterload-driven physiology: SCAPE is framed as an afterload problem with extreme sympathetic surge, so rapid vasodilation matters more than slow diuresis in the first minutes of care.
• Hypertensive patient profile: The reviewed cohort was markedly hypertensive at nitroglycerin initiation, with a median systolic pressure of 211 mmHg, reinforcing that these data apply to very high-BP pulmonary edema.
• Safety signal on hypotension: Hypotension was uncommon despite high-dose nitroglycerin, occurring in 4% of patients, which is the clearest bedside reassurance from this study.
• Composite outcome caveat: The headline unfavorable outcome was 31%, but that composite included intubation and ICU admission, outcomes that may reflect SCAPE severity more than nitroglycerin toxicity.
• Dose definition uncertainty: High dose was defined here as at least 100 mcg/min, yet the field still lacks consensus on what initiation rates are safest and most effective. We get into that practice tension in the episode.
• Alternative vasodilator question: Nicardipine is raised as a potentially better option for some SCAPE patients, a useful reminder that nitroglycerin is not the only afterload-reduction strategy worth considering.